Navigation Links
Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
Date:10/24/2007

Positive Findings Support Preclinical Development of Intradigm's ICS-283

PALO ALTO, Calif., Oct. 24 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced study results that demonstrated the company's TargeTran(TM) delivery system is capable of delivering vascular endothelial growth factor (VEGF) targeted small interfering RNAs (siRNAs) that suppress tumor-induced angiogenesis by silencing target gene expression in mice. The study findings support the preclinical development of ICS-283 a nanoparticle-based compound comprised of siRNAs that target both VEGF and its main receptor. Complete study findings were presented by Intradigm scientists today at the 2007 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

This preclinical study was designed to examine the anti-angiogenic efficacy, in multiple cancer types, of VEGF-targeted siRNAs administered systemically with Intradigm's proprietary RNAi Nanoplex(TM) delivery technology using the TargeTran(TM) delivery system. At the study's outset, tumor cells (both human colorectal and renal cell carcinoma) were implanted into a group of mice. At both two and five days post tumor cell introduction, a portion of the mice were given intravenous (IV) administration of several siRNAs targeting VEGF ligand, VEGFR1, VEGFR2, or various combinations of the three. The remaining mice received either a negative control siRNA treatment or a positive control treatment using VEGF antibody Bevacizumab. At eight days, tumor-induced angiogenesis as well as target gene knockdown were analyzed. The results showed highly significant anti-angiogenic effect that is RNAi-mediated in all active siRNA treatment groups targeting different VEGF-pathways genes.

"These study results are very encouraging as they demonstrate the ability of our RNAi Nanoplex(TM) technology to systemically deliver siRNA therapeutics direc
'/>"/>

SOURCE Intradigm Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Cardiothoracic Surgeons to Lead Pivotal TrialANN ARBOR, Mich., March ... has appointed David Seth Feldman, MD/PhD, FACC, FAHA to ... the United States, studying the new, third generation DuraHeart(TM) ... Dr. Francis Pagani, Director of the Heart Transplant and ...
... - Conference Call Today at 5:00 p.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... the fourth quarter and year ended December 31, 2008, ... of 2008, we made significant progress toward our goal ...
Cached Medicine Technology:David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 9
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, Phil ... reached Connecticut and was greeted by friends and family. He visited CCAR and left ...
(Date:7/31/2015)... ... , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA ... the Super Bowl. In the two weeks that separate the conference championships and the Super ... Super Bowl game will mark the 50th time it has been held and the festivities ...
(Date:7/31/2015)... Tenn. (PRWEB) , ... July 31, 2015 , ... The ... Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight ... focused on cancer research between Methodist Healthcare, The West Clinic and The University of ...
(Date:7/31/2015)... ... ... Coco Libre announced today that their flagship Organic Coconut Water will be ... Open of Surfing, July 25 through August 2 in Huntington Beach, California. Coco Libre, ... is a natural choice given the Open’s commitment to sustainable practices. , Designated ...
(Date:7/31/2015)... ... ... Well-known for its unique pastries and delicious confections, Pastry Palace, a popular ... life just a little bit sweeter for newlyweds. A family-owned business, the Pastry Palace ... , The bakery provides a full line of custom wedding cakes. Brides can select ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... research, taking smaller doses of caffeine throughout the day is found ... awake.// ,Based on their findings researchers say, most of ... few mugs of coffee or tea in the morning, or three ... in the brain will be falling as the day goes on. ...
... is transmitted through sexual intercourse, along with those who ... an increased risk for prostate cancer, according to new ... ,Researchers studied more than 700 black men without prostate ... Participants were asked about their sexual history. Researchers also ...
... Peanut allergy is the third most common food allergy ... allergy in older children, adolescents and adults.// Researchers studied ... Participants washed with various cleaning agents, plain water, and ... peanut butter to their hands. ,Results show hand ...
... with leukemia who died after receiving a bone marrow transplant ... evidence of the transplanted // cells up to six years ... cells were actually acting as stem cells -- basic cells ... body, and once thought to be found only in human ...
... year in the United States. Investigators have been tracking the health ... see how various factors might impact their risk for heart disease ... in those with and without a history of stroke.About 20 percent ... just 11 percent of those who didn’t have a stroke. ...
... weapon to their arsenal against type 2 diabetes. A drug ... the risk of diabetes in heart disease patients. ,For ... attack patients who received either a daily dose of the ... about six years. Men taking bezafibrate, which also lowers LDL ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: